David Lebwohl, MDEVP and Chief Medical Officer at Intellia Therapeutics
David Lebwohl, MD is the chief medical officer at Intellia Therapeutics, a genome editing company. Before Intellia, David was the chief medical officer at Semma Therapeutics Inc., and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CAR-T Teams, responsible for the development of the breakthrough therapy Kymriah® (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership, the blockbuster drug Afinitor® (everolimus) was approved for metastatic breast, neuroendocrine, and kidney cancer as well as the rare genetic disease tuberous sclerosis. David received an AB in Biochemical Sciences from Harvard College and an MD from the Yale University. He completed his fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology and his residency in internal medicine at Brigham and Women’s Hospital in Boston.